Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03746535
EARLY_PHASE1

Cardiovascular Disease Risk in Women With Endometriosis

Sponsor: Yale University

View on ClinicalTrials.gov

Summary

To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.

Official title: Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Women With Endometriosis

Key Details

Gender

FEMALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2022-07-01

Completion Date

2026-12-31

Last Updated

2025-05-23

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Elagolix

Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.

Locations (1)

Yale School of Medicine

New Haven, Connecticut, United States